arXivDaily arXiv每日学术速递 周一至周五更新
arXiv周末暂无论文更新,休息一下吧,周末愉快~~
arXiv 2605.26376cs.CVcs.AIcs.LG

BioFact-MoE:基于生物学因子分解的混合专家模型用于肝细胞癌的视觉-语言预后建模

BioFact-MoE: Biologically Factorized Mixture of Experts for Vision-Language Prognostic Modeling in Hepatocellular Carcinoma

Department of Radiology \& Biomedical Imaging, Department of Biomedical Engineering, Department of Electrical Engineering, Department of Statistics \& Data Science Yale University, New Haven, CT, 06510, USA

Junlin Yang, Tian Yu, Nicha C. Dvornek, Yuexi Du, Peiyu Duan, Annabella Shewarega, Lawrence H. Staib, James S. Duncan, Julius Chapiro

AI总结:

提出BioFact-MoE框架,通过生物学监督的混合专家模型显式分解肝脏和肿瘤因子,在肝细胞癌预后预测中提升准确性和生物学可解释性。

摘要:

肝细胞癌(HCC)具有生物学异质性,由肝功能储备和肿瘤相关肿瘤学因素之间的相互作用塑造;因此,相似的生存结果可能反映根本不同的潜在生物学过程。HCC的预后建模依赖于来自多参数MRI和常规临床实践放射学报告的丰富多模态信息。现有的预后视觉-语言模型(VLM)学习单一的纠缠潜在表示,混合了肝脏和肿瘤相关因素,限制了准确性和生物学可解释性。我们提出BioFact-MoE,一个生物学因子分解的混合专家(MoE)框架,通过残差MoE生存架构中的生物学监督专家显式分解肝脏和肿瘤因素。在N=588名患者的HCC队列(在4,582个3D MRI图像-报告对上预训练)中,BioFact-MoE在所有时间范围内持续优于所有基线的生存预测,实现了12、18和24个月的AUC分别为75.33%、75.85%和73.96%。除了标量风险预测,门控专家权重实现了表型感知的风险分层。通路感知的门控揭示了临床上有意义的治疗相关生存异质性。在保留验证中,肝脏和肿瘤嵌入分别与肝功能标志物和肿瘤负荷标志物显示出选择性关联(p<0.05),无需监督。代码可在https://github.com/jy-639/BioFact-MoE获取。

英文摘要:

Hepatocellular carcinoma (HCC) is biologically heterogeneous, shaped by the interplay between hepatic functional reserve and tumor-related oncologic factors; thus, similar survival outcomes may reflect fundamentally different underlying biological processes. Prognostic modeling in HCC is informed by rich multimodal information from multiparametric MRI and radiology reports from routine clinical practice. Existing prognostic vision-language models (VLMs) learn a single entangled latent representation that blends hepatic and tumor-related factors, limiting both accuracy and biological interpretability. We present BioFact-MoE, a biologically factorized Mixture of Experts (MoE) framework that explicitly decomposes liver and tumor factors via biologically supervised experts within a residual MoE survival architecture. On a HCC cohort of N=588 patients (pretrained on 4,582 3D MRI image-report pairs), BioFact-MoE consistently improves survival prediction over all baselines across time horizons, achieving 12-, 18-, and 24-month AUCs of 75.33%, 75.85%, and 73.96%. Beyond scalar risk prediction, gated expert weights enable phenotype-aware risk stratification. Pathway-informed gating uncovers clinically meaningful treatment-associated survival heterogeneity. In held-out validation, hepatic and tumor embeddings show selective associations with liver function and tumor burden markers, respectively (p<0.05), without supervision. The code is available at https://github.com/jy-639/BioFact-MoE.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑